Scinai Immunotherapeutics Reports Q1 Revenue of $0.59M and $1.02M in Cash and Cash Equivalents as of March 31, 2025.

Scinai Immunotherapeutics reported Q1 revenue of $0.59M, down from previous quarters. The company's cash and cash equivalents and short-term deposits decreased to $1.02M as of March 31, 2025, from $1.96M in March 2024.

Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) reported its financial results for the first quarter of 2025, revealing a decrease in revenue and a significant reduction in cash reserves. The company's revenue for the quarter ended March 31, 2025, totaled $586,000, down from the previous quarters. This decrease is attributed to lower wages and reduced direct research and development (R&D) expenses, which amounted to $1,296,000 for the quarter, compared to $1,568,000 in the same period last year [1].

The company's cash and cash equivalents and short-term deposits decreased to $1,018,000 as of March 31, 2025, from $1,964,000 in March 2024. This reduction is primarily due to the company's ongoing R&D activities and the conversion of the European Investment Bank (EIB) loan into preferred shares of the Company stock in the third quarter of 2024 [1].

Scinai's CDMO unit, which began generating revenues in the second quarter of 2024, contributed to the company's overall revenue. The CDMO business showed year-over-year growth, with revenues increasing to $586,000 in Q1 2025 from $658,000 in 2024 [1].

The company reported a net loss of $1,557,000 for the quarter, compared to a net loss of $2,159,000 in the same period last year. The improvement in net loss was primarily due to lower R&D expenses, reduced financial expenses, and the recognition of gross income [1].

Scinai's financial results for Q1 2025 indicate a challenging period for the company, with significant reductions in cash reserves and revenue. However, the company's CDMO unit continues to show growth potential. Investors should closely monitor Scinai's future financial performance and the progress of its R&D activities.

References:
[1] https://finance.yahoo.com/news/scinai-reports-q1-2025-financial-110000195.html
[2] https://seekingalpha.com/news/4453900-scinai-immunotherapeutics-reports-q1-results
[3] https://www.morningstar.com/news/pr-newswire/20250530ln99650/scinai-reports-q1-2025-financial-results-highlighting-strong-cdmo-revenue-momentum-and-reduced-cash-burn